Antioxidant capacity of Nitraria retusa leaf extracts against mitomycin C-induced genetic toxicity in male mice

Abstract Background Recently, a great interest in the usage of new derived drugs extracted from plant has been increased to treat and/or prevent several diseases including cancer. Therefore, the present study was conducted to use Nitraria retusa leaf extract to increase the antioxidant activity and reduce the genotoxic activity of chemotherapeutic drugs mitomycin C (MMC) in male mice. Male Swiss albino mice (n = 80) were divided in several experimental groups and treated with single dose of MMC with supplementation of 50 and 100 mg/kg body wt Nitraria retusa leaf extract for several time intervals (3 days, 1 week, and 1 month). Results This study found that MMC-treated mice observed significant increases in the frequency of chromosomal abnormalities in both cell types including bone marrow and spermatocyte cells, induce the mean values of DNA damage, and decrease the expression values of antioxidant enzyme-related genes (CAT, GPx, and GSTT1) compared with control mice. However, supplementation of MMC-treated mice with Nitraria retusa leaf extract suppressed the harmful impacts induced by MMC especially with the high dose and longer duration of the administration. Conclusion The results suggested that the protective capacity of the Nitraria retusa leaf extract in protecting the hepatic cells could be attributed to the presence of isorhamnetin 3-o-robinobioside, palmitic acid, and β-sitosterols in its extract which are known for their anti-tumor and anti-mutagenic activities

SMOFlipid Impact on Growth and Neonatal Morbidities in Very Preterm Infants

The soybean oil, medium-chain triglycerides, olive oil, and fish oil lipid (SMOFlipid) is increasingly being used worldwide without definite evidence of its benefits. We examined the effect of SMOFlipid on growth velocity and neonatal morbidities in very preterm infants. Very preterm infants who received soybean-based lipid emulsion between January 2015 and 2018 were compared with those who received SMOFlipids between 2019 and January 2022 in our neonatal tertiary center. Linear regression analysis was conducted to analyze the association between type of lipid emulsion and growth velocity. Modified log-Poisson regression with generalized linear models and a robust variance estimator (Huber–White) were applied to adjust for potential confounding factors. A total of 858 infants met our inclusion criteria. Of them, 238 (27.7%) received SMOFlipid. SMOFlipid was associated with lower growth velocity between birth and 36-week corrected gestational age compared with intralipid Δ weight z-score (adjusted mean difference (aMD) −0.67; 95% CI −0.69, −0.39). Subgroup analysis indicated that mainly male infants in the SMOFlipid–LE group had a lower Δ weight z-score compared to those in the intralipid group (p p = 0.82). SMOFlipid was associated with a lower rate of bronchopulmonary dysplasia (BPD) (aRR 0.61; 95% CI 0.46, 0.8) and higher rate of late-onset sepsis compared with intralipid (aRR 1.44; 95% CI 1.22–1.69). SMOFlipid was associated with lower growth velocity and BPD but higher rate of late-onset sepsis—it is a double-edged sword